BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 27333032)

  • 1. An ShRNA Screen Identifies MEIS1 as a Driver of Malignant Peripheral Nerve Sheath Tumors.
    Patel AV; Chaney KE; Choi K; Largaespada DA; Kumar AR; Ratner N
    EBioMedicine; 2016 Jul; 9():110-119. PubMed ID: 27333032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NF1 deficiency causes Bcl-xL upregulation in Schwann cells derived from neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
    Park HJ; Lee SJ; Sohn YB; Jin HS; Han JH; Kim YB; Yim H; Jeong SY
    Int J Oncol; 2013 Feb; 42(2):657-66. PubMed ID: 23292448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cdkn2a (Arf) loss drives NF1-associated atypical neurofibroma and malignant transformation.
    Rhodes SD; He Y; Smith A; Jiang L; Lu Q; Mund J; Li X; Bessler W; Qian S; Dyer W; Sandusky GE; Horvai AE; Armstrong AE; Clapp DW
    Hum Mol Genet; 2019 Aug; 28(16):2752-2762. PubMed ID: 31091306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Cellular Retinoic Acid Binding Protein 2 Promotes Survival of Malignant Peripheral Nerve Sheath Tumor Cells.
    Fischer-Huchzermeyer S; Dombrowski A; Hagel C; Mautner VF; Schittenhelm J; Harder A
    Am J Pathol; 2017 Jul; 187(7):1623-1632. PubMed ID: 28502478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brain lipid binding protein in axon-Schwann cell interactions and peripheral nerve tumorigenesis.
    Miller SJ; Li H; Rizvi TA; Huang Y; Johansson G; Bowersock J; Sidani A; Vitullo J; Vogel K; Parysek LM; DeClue JE; Ratner N
    Mol Cell Biol; 2003 Mar; 23(6):2213-24. PubMed ID: 12612091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors.
    Endo M; Yamamoto H; Setsu N; Kohashi K; Takahashi Y; Ishii T; Iida K; Matsumoto Y; Hakozaki M; Aoki M; Iwasaki H; Dobashi Y; Nishiyama K; Iwamoto Y; Oda Y
    Clin Cancer Res; 2013 Jan; 19(2):450-61. PubMed ID: 23209032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted Inhibition of the Dual Specificity Phosphatases DUSP1 and DUSP6 Suppress MPNST Growth via JNK.
    Ramkissoon A; Chaney KE; Milewski D; Williams KB; Williams RL; Choi K; Miller A; Kalin TV; Pressey JG; Szabo S; Azam M; Largaespada DA; Ratner N
    Clin Cancer Res; 2019 Jul; 25(13):4117-4127. PubMed ID: 30936125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transgenic mice overexpressing neuregulin-1 model neurofibroma-malignant peripheral nerve sheath tumor progression and implicate specific chromosomal copy number variations in tumorigenesis.
    Kazmi SJ; Byer SJ; Eckert JM; Turk AN; Huijbregts RP; Brossier NM; Grizzle WE; Mikhail FM; Roth KA; Carroll SL
    Am J Pathol; 2013 Mar; 182(3):646-67. PubMed ID: 23321323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of insulin-like growth-factor-1 receptor (IGF-1R) in peripheral nerve sheath tumors in neurofibromatosis type 1.
    Friedrich RE; Keiner D; Hagel C
    Anticancer Res; 2007; 27(4A):2085-90. PubMed ID: 17649826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues.
    Miller SJ; Rangwala F; Williams J; Ackerman P; Kong S; Jegga AG; Kaiser S; Aronow BJ; Frahm S; Kluwe L; Mautner V; Upadhyaya M; Muir D; Wallace M; Hagen J; Quelle DE; Watson MA; Perry A; Gutmann DH; Ratner N
    Cancer Res; 2006 Mar; 66(5):2584-91. PubMed ID: 16510576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RAS/MEK-independent gene expression reveals BMP2-related malignant phenotypes in the Nf1-deficient MPNST.
    Sun D; Haddad R; Kraniak JM; Horne SD; Tainsky MA
    Mol Cancer Res; 2013 Jun; 11(6):616-27. PubMed ID: 23423222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.
    Patel AV; Eaves D; Jessen WJ; Rizvi TA; Ecsedy JA; Qian MG; Aronow BJ; Perentesis JP; Serra E; Cripe TP; Miller SJ; Ratner N
    Clin Cancer Res; 2012 Sep; 18(18):5020-30. PubMed ID: 22811580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor suppressor mutations and growth factor signaling in the pathogenesis of NF1-associated peripheral nerve sheath tumors: II. The role of dysregulated growth factor signaling.
    Carroll SL; Stonecypher MS
    J Neuropathol Exp Neurol; 2005 Jan; 64(1):1-9. PubMed ID: 15715079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Schwann cell lines derived from malignant peripheral nerve sheath tumors respond abnormally to platelet-derived growth factor-BB.
    Dang I; DeVries GH
    J Neurosci Res; 2005 Feb; 79(3):318-28. PubMed ID: 15602756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular characterization of permanent cell lines from primary, metastatic and recurrent malignant peripheral nerve sheath tumors (MPNST) with underlying neurofibromatosis-1.
    Fang Y; Elahi A; Denley RC; Rao PH; Brennan MF; Jhanwar SC
    Anticancer Res; 2009 Apr; 29(4):1255-62. PubMed ID: 19414372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression patterns of cell cycle components in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors.
    Agesen TH; Flørenes VA; Molenaar WM; Lind GE; Berner JM; Plaat BE; Komdeur R; Myklebost O; van den Berg E; Lothe RA
    J Neuropathol Exp Neurol; 2005 Jan; 64(1):74-81. PubMed ID: 15715087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ErbB4 promotes malignant peripheral nerve sheath tumor pathogenesis via Ras-independent mechanisms.
    Longo JF; Brosius SN; Black L; Worley SH; Wilson RC; Roth KA; Carroll SL
    Cell Commun Signal; 2019 Jul; 17(1):74. PubMed ID: 31291965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumours.
    Subramanian S; Thayanithy V; West RB; Lee CH; Beck AH; Zhu S; Downs-Kelly E; Montgomery K; Goldblum JR; Hogendoorn PC; Corless CL; Oliveira AM; Dry SM; Nielsen TO; Rubin BP; Fletcher JA; Fletcher CD; van de Rijn M
    J Pathol; 2010 Jan; 220(1):58-70. PubMed ID: 19890883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.
    Brundage ME; Tandon P; Eaves DW; Williams JP; Miller SJ; Hennigan RH; Jegga A; Cripe TP; Ratner N
    Oncogene; 2014 Dec; 33(49):5626-36. PubMed ID: 24509877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ral overactivation in malignant peripheral nerve sheath tumors.
    Bodempudi V; Yamoutpoor F; Pan W; Dudek AZ; Esfandyari T; Piedra M; Babovick-Vuksanovic D; Woo RA; Mautner VF; Kluwe L; Clapp DW; De Vries GH; Thomas SL; Kurtz A; Parada LF; Farassati F
    Mol Cell Biol; 2009 Jul; 29(14):3964-74. PubMed ID: 19414599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.